HS

Heska CorpNASDAQ HSKA Stock Report

Last reporting period 31 Mar, 2023

Updated —

Last price

Market cap $B

1.31

Small

Exchange

XNAS - Nasdaq

HSKA Stock Analysis

HS

Uncovered

Heska Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-6/100

Low score

Market cap $B

1.31

Dividend yield

Shares outstanding

10.876 B

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. The company is headquartered in Loveland, Colorado and currently employs 808 full-time employees. The firm's North America segment consists of the contract manufacturing of vaccines and pharmaceutical products. Its International segment consists of geographies outside of North America, primarily its operations in Australia, France, Germany, Italy, Malaysia, Spain and Switzerland. Its veterinary instruments include Element RC, Element RCX and Element RC3X. Its offerings include Point of Care diagnostic laboratory instruments and consumables; Point of Care digital imaging diagnostic products; reference laboratory testing; digital cytology services; vaccines; local and cloud-based data services; allergy testing and immunotherapy; single-use offerings such as in-clinic diagnostic tests and heartworm preventive products, and practice information management software and related software. The firm also provides planar waveguide fluorescence immunoassay diagnostics.

View Section: Eyestock Rating